Global Empagliflozin, Dapagliflozin and Canagliflozin Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Empagliflozin, Dapagliflozin and Canagliflozin Market Analysis

The global empagliflozin, dapagliflozin, and canagliflozin market is driven by the increasing prevalence of type 2 diabetes mellitus (T2DM), which affects an estimated 537 million adults globally as of 2021, a figure projected to rise to 783 million by 2045, according to the International Diabetes Federation (IDF). These sodium-glucose cotransporter-2 (SGLT2) inhibitors have gained traction due to their proven efficacy in reducing cardiovascular risks and managing chronic kidney disease (CKD), conditions that affect a significant portion of diabetic patients. For instance, nearly 40% of individuals with diabetes develop CKD, further highlighting the importance of these therapies. Additionally, advancements in combination therapies, such as those pairing SGLT2 inhibitors with metformin or DPP-4 inhibitors, have enhanced patient compliance and outcomes, broadening the market's potential. The growing burden of diabetes-related complications worldwide is expected to sustain the demand for these drugs in both developed and emerging markets.

Empagliflozin, Dapagliflozin and Canagliflozin Market Size

Global empagliflozin, dapagliflozin and canagliflozin market size was valued at USD 6.28 billion in 2024 and is projected to reach USD 11.05 billion by 2032, with a CAGR of 7.25% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Empagliflozin, Dapagliflozin and Canagliflozin Market Trends

“Shift Towards Utilizing SGLT2 Inhibitors for Preventative Care”

There is a growing emphasis on utilizing SGLT2 inhibitors for early intervention in pre-diabetic and high-risk populations. Clinical research highlights the potential of these medications in delaying the onset of type 2 diabetes and associated complications by improving glycemic control and providing protective cardiovascular and renal benefits. This trend reflects a broader strategy within healthcare to manage metabolic disorders before they progress to advanced stages, which often lead to costly and complex treatments. Early use of SGLT2 inhibitors in individuals with impaired glucose tolerance or those at risk of developing diabetes aligns with global public health initiatives aimed at reducing the long-term burden of chronic diseases.

Report Scope and Empagliflozin, Dapagliflozin and Canagliflozin Market Segmentation

Empagliflozin, Dapagliflozin and Canagliflozin Market Definition

Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor used to lower blood glucose levels by reducing glucose reabsorption in the kidneys and promoting its excretion in urine. It is primarily prescribed for managing type 2 diabetes and has additional benefits in reducing cardiovascular risks and slowing the progression of kidney disease. Dapagliflozin is an SGLT2 inhibitor that aids in managing type 2 diabetes by preventing glucose reabsorption in the kidneys, leading to increased glucose excretion. It is also approved for use in patients with heart failure and chronic kidney disease, providing protective cardiovascular and renal effects. Canagliflozin is another SGLT2 inhibitor that works by blocking glucose reabsorption in the kidneys, thereby helping control blood sugar levels in type 2 diabetes. It has shown efficacy in reducing the risk of cardiovascular events and slowing the progression of kidney disease in diabetic patients.

Empagliflozin, Dapagliflozin and Canagliflozin Market Dynamics

Drivers  

• Rising Prevalence of Type 2 Diabetes

The global prevalence of type 2 diabetes is rapidly increasing, with over 537 million adults aged 20-79 years affected in 2021. This growing burden is largely attributed to factors such as unhealthy diets, sedentary lifestyles, and aging populations. As a result, there is a rising demand for effective therapies to manage blood glucose levels and reduce the risk of complications. SGLT2 inhibitors, including Empagliflozin, Dapagliflozin, and Canagliflozin, have emerged as critical treatments for type 2 diabetes, not only helping to control blood sugar but also offering additional benefits, such as reducing cardiovascular risks and slowing kidney disease progression. The projected rise to 783 million diabetes cases by 2045 underscores the escalating need for these innovative therapies. As more patients seek treatment for managing diabetes and its associated complications, the demand for SGLT2 inhibitors will continue to expand, making them an essential part of diabetes care worldwide. For instance, in June 2024, according to an article published by NCBI, the number of people affected by diabetes in India has risen sharply, from 33 million in 2000 to 72 million in 2021, with projections indicating it could reach 125 million by 2045. This growing prevalence of diabetes is expected to drive demand for effective treatments and therapies, creating significant opportunities for the SGLT2 inhibitors market to expand in India.

• Favorable Clinical Guidelines and Recommendations   

Favorable clinical guidelines and recommendations have played a key role in driving the adoption of SGLT2 inhibitors such as Empagliflozin, Dapagliflozin, and Canagliflozin in the management of diabetes and related comorbidities. Leading health organizations, including the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), have endorsed these drugs for patients with type 2 diabetes and associated complications such as cardiovascular disease and chronic kidney disease. These endorsements, which recognize the dual benefits of SGLT2 inhibitors in glycemic control and organ protection, have significantly influenced clinical practices. As a result, healthcare providers are increasingly prescribing these therapies, given their proven efficacy and positive impact on patient outcomes. The guidance from these reputable organizations has helped build confidence among physicians, driving a wider adoption of SGLT2 inhibitors, thereby accelerating market growth and enhancing their role in diabetes care. In April 2024, according to an article published by International Society of Nephrology, the 2024 update of the KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD) is based on the latest evidence. This updated guideline is expected to drive the increased use of SGLT2 inhibitors in CKD management, as it highlights their effectiveness in slowing disease progression and improving patient outcomes, thereby enhancing their adoption in clinical practice.

Opportunities

• Pipeline Development for New Indications

Ongoing clinical trials exploring new indications for SGLT2 inhibitors such as Empagliflozin, Dapagliflozin, and Canagliflozin are unlocking significant opportunities for market expansion. Research into conditions such as non-alcoholic fatty liver disease (NAFLD) and type 1 diabetes suggests that these drugs may offer benefits beyond their current use in type 2 diabetes. In NAFLD, where liver fat accumulation leads to inflammation and fibrosis, SGLT2 inhibitors have shown promise in improving liver health and reducing associated risks. For type 1 diabetes, these medications are being studied for their potential to assist in glucose control and reduce the risk of complications, which could greatly benefit patients who have limited treatment options. If approved, these broader therapeutic applications could significantly increase the market size, addressing underserved patient populations and enhancing the overall value of SGLT2 inhibitors in the treatment of various metabolic and cardiovascular conditions. For Instance, In June 2023, according to an article published by NCBI, Canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin are FDA-approved SGLT2 inhibitors used alongside diet and exercise to manage type 2 diabetes mellitus (DM) by reducing glucose reabsorption in the kidneys and increasing urinary glucose excretion. This class of drugs is expected to create growth opportunities as ongoing research explores their potential for new indications, such as type 1 diabetes and non-alcoholic fatty liver disease (NAFLD), thus broadening their therapeutic application and market potential.

• Advancements in Fixed-Dose Combination Therapies

Advancements in fixed-dose combination therapies (FDCs) are creating significant opportunities for the global market of SGLT2 inhibitors such as Empagliflozin, Dapagliflozin, and Canagliflozin. These FDCs combine SGLT2 inhibitors with other classes of diabetes medications, such as GLP-1 receptor agonists, DPP-4 inhibitors, or insulin, to simplify treatment regimens. By combining multiple drugs into a single pill, FDCs enhance patient adherence, reducing the burden of managing complex regimens. These combinations can also improve overall glycemic control by targeting different mechanisms of action simultaneously, which is particularly beneficial for patients with complex conditions such as uncontrolled diabetes, cardiovascular disease, or kidney disease. As more FDCs enter the market, they are expected to broaden the accessibility of SGLT2 inhibitors to a wider range of patients, including those with multiple comorbidities. This development is set to drive the adoption of Empagliflozin, Dapagliflozin, and Canagliflozin, fueling further market growth. For instance, in March 2024, according to an article published by NCBI, Health Canada has approved six SGLT2 inhibitors and fixed-dose combination products for type 2 diabetes, including dapagliflozin, canagliflozin, and empagliflozin with metformin. This approval reflects the growing trend of fixed-dose combination therapies, enhancing treatment convenience and patient adherence, which is expected to drive market growth.

Restraints/Challenges

• High Cost of SGLT2 Inhibitors

The high cost of SGLT2 inhibitors such as Empagliflozin, Dapagliflozin, and Canagliflozin is a major restraint in their market growth. These medications are generally more expensive compared to other traditional diabetes treatments, making them less accessible, especially in low-income and middle-income countries. The financial burden is significant for both healthcare systems and patients, particularly in regions where health insurance coverage is limited or inadequate. In many cases, patients may be unable to afford these therapies out-of-pocket, especially when alternatives such as generic diabetes drugs are available at a much lower price. This cost disparity can limit the adoption of SGLT2 inhibitors, especially in resource-constrained settings, where budget constraints significantly affect healthcare expenditures. Even though these drugs offer advanced benefits in managing diabetes and related complications, their high cost continues to be a barrier to widespread use, thus slowing down the overall growth of the market.    

• Safety Concerns and Side Effects

Safety concerns and side effects pose a significant challenge to the global market for SGLT2 inhibitors such as Empagliflozin, Dapagliflozin, and Canagliflozin. Although these drugs are highly effective in managing type 2 diabetes and related conditions, they are associated with several potential side effects, including genital infections, urinary tract infections, dehydration, and hypotension. Furthermore, Canagliflozin has been linked to an increased risk of lower limb amputations, especially in certain patient populations with pre-existing conditions such as peripheral arterial disease. These safety concerns may cause hesitancy among healthcare providers to prescribe these drugs, particularly for high-risk patients or those with complicating health conditions. Patients experiencing adverse effects may also discontinue treatment, which can negatively impact adherence and long-term therapeutic outcomes. Therefore, addressing these safety concerns is essential for the growth of the market, as they directly affect both physician prescribing habits and patient acceptance of the therapy. In June 2024, according to an article published by Journal of Endocrinology & Metabolism, The most frequent adverse effect of SGLT2 inhibitors is an increased risk of urogenital infections caused by glucosuria and osmotic diuresis. While less common, euglycemic ketoacidosis and acute kidney injury have been reported in rare cases, such as with remogliflozin. These safety concerns present a challenge, as they may impact patient adherence and physician willingness to prescribe these therapies, potentially limiting their broader use in clinical practice.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Empagliflozin, Dapagliflozin and Canagliflozin Market Scope

The market is segmented on the basis of drug type, dosage form, application, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Type

• Empagliflozin
• Dapagliflozin
• Canagliflozin

Dosage Form

• Tablets
• Combination Drugs

Application

• Type 2 Diabetes Mellitus (T2DM) Treatment
• Cardiovascular Disease Management
• Chronic Kidney Disease Management

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Empagliflozin, Dapagliflozin and Canagliflozin Market Regional Analysis

The market is analyzed and market size insights and trends are provided by country, drug type, dosage form, application, and distribution channel as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.

North America is expected to dominate the market due to several critical factors. The region has a high prevalence of type 2 diabetes, a key driver for the adoption of sodium-glucose cotransporter-2 (SGLT2) inhibitors such as these drugs. The growing burden of diabetes is prompting increased demand for effective treatment options that not only manage blood glucose levels but also offer additional benefits such as cardiovascular and renal protection.

Asia-Pacific is expected to be the fastest growing due to several critical factors. The rising incidence of type 2 diabetes across the region, particularly in densely populated countries such as India, China, and Indonesia, is a major growth driver. Urbanization, sedentary lifestyles, and dietary changes have significantly contributed to the escalating prevalence of diabetes, increasing the demand for effective therapeutic options such as SGLT2 inhibitors.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Empagliflozin, Dapagliflozin and Canagliflozin Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Empagliflozin, Dapagliflozin and Canagliflozin Market Leaders Operating in the Market Are:

• Boehringer Ingelheim International GmbH (Germany)
• Eli Lilly and Company  (U.S.)
• AstraZeneca (UK)
• Johnson & Johnson Services, Inc. (U.S.)
• Merck & Co., Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Sanofi (France)
• Bayer AG (Germany)
• Novartis AG (Switzerland)
• Teva Pharmaceutical Industries (Israel)
• Sun Pharmaceutical Industries Ltd. (India)
• Lupin Limited (India)
• Aurobindo Pharma (India)
• Cipla Limited (India)
• GLENMARK PHARMACEUTICALS LTD. (India)
• Viatris Inc. (U.S.)
• Dr. Reddy's Laboratories (India)
• Mitsubishi Tanabe Pharma Corporation (Japan)
• Abbott (U.S.)

Latest Developments in Empagliflozin, Dapagliflozin and Canagliflozin Market

• In December 2024, Torrent Pharmaceuticals has announced an agreement to acquire three anti-diabetes brands from Boehringer Ingelheim International GmbH (BI). This acquisition will enable Torrent to enhance its portfolio in the diabetes care market, allowing the company to broaden its therapeutic offerings and expand its reach in a rapidly growing global market

SKU-73179